OncoSil Medical (ASX:OSL) achieved 50% of its target recruits for its TRIPP-FFX clinical trial, with the 40th patient randomized, according to a Thursday filing with the Australian bourse.

The trial aims to assess the safety and efficacy of OncoSil when given in addition to standard Folfirinox chemotherapy in treating locally advanced pancreatic cancer, the filing stated.

Meanwhile, the company reached the halfway point of patient recruitment in its Pancosil clinical trial, with the 10th patient treated, the filing said.

The trial is evaluating the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil device in patients with non-progressive locally advanced pancreatic cancer.

The medical device company's shares surged almost 8% in recent Friday trade.

Price (AUD): $0.01, Change: $+0.0010, Percent Change: +7.69%